Rating Rationale
October 15, 2024 | Mumbai
Cian Healthcare Limited
Rating reaffirmed at ‘CRISIL D'
 
Rating Action
Total Bank Loan Facilities RatedRs.44 Crore
Long Term RatingCRISIL D (Reaffirmed)
Note: None of the Directors on CRISIL Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed rationale

CRISIL Ratings has reaffirmed its ‘CRISIL D’ rating on the long-term bank facilities of Cian Healthcare Ltd (CHL).

 

The rating is driven by delays in servicing term loans and working capital lines.

 

The rating reflects CHL’s below-average financial risk profile, driven by weak debt protection metrics, large working requirement with average scale, and exposure to regulatory risks and volatility in the prices of raw materials. These weaknesses are partially offset by the extensive experience of the promoters in the pharmaceutical industry and CHL's product and geographical diversification in revenue.

 

CRISIL Ratings also notes that the corporate insolvency resolution process (CIRP) against CHL is undergoing.

Analytical approach

Unsecured loan of Rs 6.59 crore, as on March 31, 2024, provided by the promoters and their friends and relatives has been treated as neither debt nor equity as the loan is expected to be retained in the business over the medium term.

Key rating drivers and detailed description

Weaknesses:

  • Below-average financial risk profile: Suppressed profitability and large debt levels have constrained the company’s financial risk profile. CHL’s interest coverage and net cash accrual to total debt (NCATD) ratios were weak at 1.79 times and 0.15 time, respectively, in fiscal 2024. As the company’s profitability continues to remain under pressure, these metrics are expected to remain subdued in the near to medium term. Its capital structure remains moderate, driven by below average networth.

 

  • Average scale and large working capital requirement: Intense competition restricts scalability of operations, as reflected in topline of around Rs 59 crore in fiscal 2024. Also, revenue has remained average at Rs 59-67 crore in the three fiscals through 2024.

 

Gross current assets were 349-391 days over the three fiscals ended March 31, 2024. Large working capital requirement arises from high debtor and inventory levels. It is required to extend long credit period. The working capital requirement may remain high over the medium term, given the business model.

 

  • Exposure to regulatory risks and volatility in prices of raw materials: The pharmaceutical industry is a closely monitored and regulated industry, and hence, inherent risks and liabilities associated with products and their manufacturing persist. Furthermore, prices of key raw materials, active pharmaceuticals ingredients, are volatile. Hence, profitability is susceptible to fluctuations in raw material prices.

 

Strengths:

  • Extensive industry experience of the promoters: The promoters have more than 15 years’ experience in the pharmaceuticals formulation industry. This has given them a strong understanding of the market dynamics and enabled them to establish healthy relationships with suppliers and customers.

 

  • Product and geographical diversification in revenue: CHL has a diversified product portfolio including tablets, capsules, ointments, sachet, liquid, syrups, dry powder, injectables, protein powders, nutraceutical supplements, lotions, creams, medicated soaps, medicated shampoos, among others, which are marketed through 600 different brands. The company has registered over 200 molecules under its own name. It caters to diverse segments including gynecology, hematinic, cardio-diabetic, orthopedic, pediatric, derma-cosmetic, antibiotic, central nervous system, and vitamins and nutrient products. Furthermore, the company sells its products across India and exports to overseas countries, thus geographically diversifying its revenue profile.

Liquidity: Poor

Bank limit utilisation was high with almost full utilisation. The company had instances of delays in servicing of term loan and working capital lines.

Rating sensitivity factors

Upward factors

  • Track record of timely debt servicing for at least more than 90 days.
  • Improvement in the financial and liquidity risk profiles.

About the company

CHL was incorporated in January 2003 and was listed on the Bombay Stock Exchange (BSE: SME) in May 2019. The company manufactures pharmaceutical formulations in the form of tablets, capsules, liquid orals, ointments, creams, lotions, gels and sachets. CHL markets its products under the brand name, CIAN. It has two manufacturing facilities in Roorkee, Uttarakhand. CHL is promoted by Mr Suraj Zanwar and his family members.

 

CHL has a subsidiary, Dr Smith Biotic Pvt Ltd, which manufactures cosmetics and toiletries that includes pre-shave, shaving or after-shave preparations, personal deodorants and antiperspirants, perfumed bath salts and other bath preparations, beauty or make-up preparations. The subsidiary is ramping up its operations and is not expected to require any funding support from CHL going forward.

Key financial indicators

As on/for the period ended March 31

Unit

2024

2023

Operating income

Rs crore

59.63

67.68

Reported profit after tax (PAT)

Rs crore

0.39

1.08

PAT margin

%

0.7

1.59

Adjusted debt/adjusted networth

Times

0.79

0.79

Interest coverage

Times

1.79

2.01

Any other information: Not Applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN Name Of Instrument Date Of Allotment Coupon Rate (%) Maturity Date Issue Size (Rs. Crore) Complexity Levels Rating Outstanding with Outlook
NA Cash Credit NA NA NA 21.50 NA CRISIL D
NA Proposed Fund-Based Bank Limits NA NA NA 4.52 NA CRISIL D
NA Term Loan NA NA 31-Mar-26 1.47 NA CRISIL D
NA Term Loan NA NA 31-Mar-26 2.31 NA CRISIL D
NA Term Loan NA NA 31-Mar-26 4.22 NA CRISIL D
NA Term Loan NA NA 31-Mar-26 9.98 NA CRISIL D
Annexure - Rating History for last 3 Years
  Current 2024 (History) 2023  2022  2021  Start of 2021
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 44.0 CRISIL D   -- 18-07-23 CRISIL D   --   -- --
      --   -- 15-05-23 CRISIL B+/Stable   --   -- --
      --   -- 03-03-23 CRISIL B+/Stable   --   -- --
      --   -- 27-02-23 CRISIL B+/Stable   --   -- --
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Cash Credit 3.4 Bank of Baroda CRISIL D
Cash Credit 5.7 Union Bank of India CRISIL D
Cash Credit 12.4 IDBI Bank Limited CRISIL D
Proposed Fund-Based Bank Limits 4.52 Not Applicable CRISIL D
Term Loan 2.31 Union Bank of India CRISIL D
Term Loan 4.22 Small Industries Development Bank of India CRISIL D
Term Loan 1.47 IDBI Bank Limited CRISIL D
Term Loan 9.98 Bank of Baroda CRISIL D
Criteria Details
Links to related criteria
CRISILs Bank Loan Ratings - process, scale and default recognition
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies

Media Relations
Analytical Contacts
Customer Service Helpdesk

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Himank Sharma
Director
CRISIL Ratings Limited
D:+91 124 672 2152
himank.sharma@crisil.com


Ankita Gupta
Associate Director
CRISIL Ratings Limited
D:+91 22 4097 8104
ankita.gupta@crisil.com


Vishnu Patel
Senior Rating Analyst
CRISIL Ratings Limited
B:+91 20 4018 1900
Vishnu.Patel@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited, an S&P Global Company)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).

CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").

For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a leading, agile and innovative global analytics company driven by its mission of making markets function better. 

It is India’s foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') provided by CRISIL Ratings Limited ('CRISIL Ratings'). For the avoidance of doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for use only within the jurisdiction of India. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings provision or intention to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

The report is a statement of opinion as on the date it is expressed, and it is not intended to and does not constitute investment advice within meaning of any laws or regulations (including US laws and regulations). The report is not an offer to sell or an offer to purchase or subscribe to any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way.

CRISIL Ratings and its associates do not act as a fiduciary. The report is based on the information believed to be reliable as of the date it is published, CRISIL Ratings does not perform an audit or undertake due diligence or independent verification of any information it receives and/or relies on for preparation of the report. THE REPORT IS PROVIDED ON “AS IS” BASIS. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAWS, CRISIL RATINGS DISCLAIMS WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR OTHER WARRANTIES OR CONDITIONS, INCLUDING WARRANTIES OF MERCHANTABILITY, ACCURACY, COMPLETENESS, ERROR-FREE, NON-INFRINGEMENT, NON-INTERRUPTION, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE OR INTENDED USAGE. In no event shall CRISIL Ratings, its associates, third-party providers, as well as their directors, officers, shareholders, employees or agents be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

The report is confidential information of CRISIL Ratings and CRISIL Ratings reserves all rights, titles and interest in the rating report. The report shall not be altered, disseminated, distributed, redistributed, licensed, sub-licensed, sold, assigned or published any content thereof or offer access to any third party without prior written consent of CRISIL Ratings.

CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains or its associates. Ratings are subject to revision or withdrawal at any time by CRISIL Ratings. CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.

CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For more detail, please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the Securities and Exchange Board of India regulations (and other applicable regulations, if any), are made available on its websites, www.crisilratings.com and https://www.ratingsanalytica.com (free of charge). CRISIL Ratings shall not have the obligation to update the information in the CRISIL Ratings report following its publication although CRISIL Ratings may disseminate its opinion and/or analysis. Reports with more detail and additional information may be available for subscription at a fee.  Rating criteria by CRISIL Ratings are available on the CRISIL Ratings website, www.crisilratings.com. For the latest rating information on any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisilratings.com/en/home/our-business/ratings/credit-ratings-scale.html